Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
May 06, 2019 16:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 28, 2019 16:00 ET
|
Capricor Therapeutics, Inc.
Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
March 21, 2019 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
February 06, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients...
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
January 24, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
January 22, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive...
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 16:01 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
November 12, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
FibroGen Reports Third Quarter 2018 Financial Results
November 08, 2018 16:02 ET
|
FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
November 08, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action...